{"url_path":"/sec/tovx/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed”","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-072633-index.html","accession_number":"0001104659-26-072633","cik":"0000894158","ticker":"TOVX","issuer_name":"Theriva Biologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-072633-index.html","primary_entity_key":"0000894158","primary_entity_name":"Theriva Biologics, Inc."},"word_count":140,"has_tables":true,"body_markdown":"Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed”\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section\nor Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with\nthe U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general\nincorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe\nharbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements\ncontained therein are “forward-looking” rather than historical."}